CLINICAL_TRIALS
trial_result
· 2016-12-07
Clinical Trial Update: Safety and Tolerability Study of SHP626 in Overweight and Obese Adults [Phase 1]
Summary
Phase 1 safety and tolerability trial of SHP626 in overweight and obese adults with non-alcoholic steatohepatitis has completed with posted results in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Non-Alcoholic Steatohepatitis | Phase 1 | Status: COMPLETED | Results posted: 2016-12-07